BOTHELL, Wash, Jan. 30 /PRNewswire-FirstCall/ -- Cardiac Science
Corporation (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis,
resuscitation, rehabilitation, and informatics products, today highlighted
two high-profile contracts secured by its corporate accounts sales team.
With these contracts, Cardiac Science will supply Powerheart(R) automated
external defibrillators (AEDs) and program management services to hundreds
of locations worldwide.
The recent Cardiac Science deals are with the following companies:
-- CH2M HILL -- Cardiac Science signed an exclusive five-year deal to
supply Powerheart AEDs and program management services at all of CH2M
HILL's locations in the United States. CH2M HILL is a global leader
in engineering, construction and operations for public and private
clients with more than 23,000 employees in offices around the world.
-- Cummins Engine (NYSE: CMI) -- Cardiac Science signed an exclusive deal
to supply its Powerheart AEDs and program management services for all
of Cummins Engine's 222 worldwide locations. Also, the Powerheart
AEDs will replace another manufacturer's AEDs in a number of Cummins'
facilities. A $12-billion company with 34,000 employees worldwide,
Cummins Engine is a major manufacturer of diesel engines and power
"Our global corporate deployment capabilities are at the heart of our AED sales strategy. These recent wins demonstrate our continued success in this area," said John Hinson, Cardiac Science president and chief executive officer.
Fifteen minutes after a Cummins Engine employee learned how to use a Powerheart AED, he saved a colleague's life.
"There is a real need for accessible defibrillation in the workplace," added Mr. Hinson. "According to the Occupational Safety & Health Administration, 15% of all workplace fatalities are sudden cardiac arrests. That we were able to play such a vital role in a life saving event so soon after deployment underscores the value and importance of the products and services we provide. We applaud Cummins and CH2M HILL for their commitment to creating heart safe environments at their locations worldwide."
Cardiac Science's global program management services help customers comply with applicable regulatory requirements and practical logistics issues concerning AED placement and usage. This includes American Heart Association certified training, meticulous record keeping, and a licensed physician to oversee the program.
About Cardiac Science Corporation
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including AEDs, electrocardiographs, stress test systems, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other systems. The Company sells a variety of related products and consumables, and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), Powerheart(R), Quinton(R), and HeartCentrix(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in the North America, Europe, and Asia. For information, call 425-402-2000 or visit http://www.cardiacscience.com.
This press release contains forward-looking statements including, but
not limited to, those that infer that Cardiac Science Corporation's future
revenue and profits may grow as a result of sales of defibrillation
products. These statements and their underlying assumptions involve a
number of risks and uncertainties and are not guarantees of future
performance. These are forward-looking statements for purposes of the safe
harbor provisions under the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "intend," anticipate," variations of
such words, and similar expressions identify forward-looking statements,
but their absence does not mean that the statement is not forward looking.
Actual results may vary significantly from the results expressed or implied
in such statements. Factors that could cause or contribute to such varying
results and other risks are more fully described in the Annual Report on
Form 10-K filed by Cardiac Science Corporation for the year ended December
31, 2006. Cardiac Science Corporation undertakes no duty or obligation to
update the information provided herein.
Cardiac Science Corporation Contact:
Cardiac Science Corporation
Sr. Vice President and CFO
EVC Group, Inc.
EVC Group, Inc.
|SOURCE Cardiac Science Corporation|
Copyright©2008 PR Newswire.
All rights reserved